A Japanese health ministry proposal to impose steeper price cuts on certain medicines deemed to carry poor cost-effectiveness profiles cleared…
HOME > TOP STORIES
TOP STORIES
-
COMMENTARY With Honebuto 2024 Looming, Now Is the Time to Revisit Social Security Spending
April 2, 2024
-
BUSINESS New Ono Chief Eager to Go Solo in US, Europe; BTK Med 1st Shield against Opdivo Patent Cliff
April 1, 2024
-
BUSINESS Parexel Helping Japan Address Drug Loss with “Ethnobridging” Studies, PI Still a Hurdle
March 29, 2024
-
REGULATORY MHLW Generic Panel Outlines Plan to Drive Industry Revamp within Specific Time Frame
March 28, 2024
-
REGULATORY Japan Approves Piasky, Beyfortus, Broader Use for Abrysvo, and Lot More
March 27, 2024
-
ORGANIZATION Backed by 12 Pharmas, US Nonprofit’s Cloud Platform Now Up and Running to Streamline Regulatory Submissions
March 26, 2024
-
REGULATORY Chuikyo Agrees to Exempt PD-1/PD-L1, JAK Classes from Spillover Re-Pricing
March 25, 2024
-
REGULATORY Xocova’s Price to Remain Intact after Full Approval, No Change in Clinical Positioning
March 25, 2024
-
REGULATORY Pharma Regulation Panel Wraps Up Debate, Report to Be Finalized Soon
March 22, 2024
-
REGULATORY Japan Resumes Debate on Rx-to-OTC Switch of PPIs after Over 5 Years
March 22, 2024
-
BUSINESS Will Kyowa Kirin’s Eye Drops for nAMD Replace Intraocular Injections? PII Now Underway
March 21, 2024
-
BUSINESS Meiji’s Bivalent COVID Jab Hits Primary Goal in PIII Omicron Trial; New Strains Eyed
March 21, 2024
-
REGULATORY Japan Mulls Simplifying Drug Delisting Process to Help Ensure Stable Supplies
March 19, 2024
-
BUSINESS FY2024 Revision Rates Tallied for Each Firm’s Top 5 Meds; Fuso Logs Price Hike Too on Infusion Products
March 18, 2024
-
BUSINESS Sumitomo Offloads Entire Ulotaront Rights to Otsuka for Strategic Priorities
March 18, 2024
-
REGULATORY Japan to Present Class-by-Class Generic Shares to Hit New Goals: Minister
March 18, 2024
-
REGULATORY Japan Begins Discussions on RSV Vaccines for National Immunization Program
March 15, 2024
-
BUSINESS Takeda Settles on Lower Pay Hike than 2023; Union Group Says Pharma Labor Talks Tougher than Others
March 15, 2024
-
REGULATORY PD-1/PD-L1, JAK Drugs to Be Exempt from Spillover Price Cuts: Chuikyo
March 14, 2024
-
REGULATORY Lagevrio, Kerendia Braced for Price Cuts after Cost-Effectiveness Assessment
March 14, 2024
ページ
A Japanese drug pricing panel on November 11 discussed ways to respond to the US most-favored-nation (MFN) policy, with healthcare…
On paper, things should be looking up for Japan’s pharmaceutical wholesalers. Industry expectations are mounting that the average gap between NHI and market prices will narrow further in FY2026 from the previous year’s record low of 4.8%.A shrinking gap should…
Japan is set to add 16 new drugs to its NHI reimbursement price list on November 13, including a subcutaneous…
Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…